Exenatide

How Exenatide works

Exenatide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. Its short half-life concentrates its pharmacodynamic effect around meals rather than providing continuous receptor coverage, which distinguishes it from the long-acting agents in the class.

What research has looked at

• Primary endpoint across the registrational program: HbA1c reduction as an adjunct to diet and exercise in adults with type 2 diabetes. In the 24-week monotherapy trial the placebo-adjusted HbA1c change was -0.5 percent at the starting dose level and -0.7 percent at the maintenance dose level, with 48 and 53 percent of patients reaching HbA1c below 7 percent versus 38 percent on placebo.
• Secondary endpoint: modest weight reduction, placebo-adjusted -1.3 kg and -1.5 kg at 24 weeks in the monotherapy trial. Weight loss is not an approved indication for exenatide.
• Exploratory subset finding, not a primary or full-population endpoint: postprandial glucose was measured by mixed-meal tolerance test in only about 9.5 percent of patients pooled across the three 30-week add-on trials, where exenatide lowered 2-hour postprandial glucose in a dose-dependent manner. Sample size is small and the analysis was not the basis of approval, so it should not be presented as a headline efficacy claim.
• Cardiovascular outcomes evidence exists only for the extended-release formulation, not for this immediate-release product, and it is a neutral safety result rather than a demonstrated benefit. In EXSCEL (14,752 participants, median follow-up 3.2 years) the primary composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke did not reach superiority (hazard ratio 0.91, 95 percent CI 0.83 to 1.00, p=0.061); the non-inferiority criterion for cardiovascular safety was met.
• No exenatide product carries a cardiovascular risk-reduction indication.

Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.

Reported side effects and risks

• Contraindicated after a prior severe hypersensitivity reaction to exenatide or any of its excipients; serious reactions including anaphylaxis and angioedema have been reported.
• Contraindicated in anyone with a history of drug-induced immune-mediated thrombocytopenia from an exenatide product; serious bleeding, which may be fatal, has been reported.
• Acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis, has been reported. Discontinue if pancreatitis is suspected.
• Not recommended in end-stage renal disease or severe renal impairment (creatinine clearance below 30 mL/min), and use with caution after renal transplantation. In patients with end-stage renal disease on dialysis, single doses were poorly tolerated because of gastrointestinal adverse reactions.
• Acute kidney injury due to volume depletion and worsening of chronic renal failure, sometimes requiring dialysis; monitor renal function in patients reporting reactions that could cause volume depletion.
• Severe gastrointestinal adverse reactions; exenatide is not recommended in patients with severe gastroparesis.
• Immunogenicity: patients may develop anti-exenatide antibodies. If glycemic control worsens or target glycemic control is not achieved, consider alternative antidiabetic therapy.
• Hypoglycemia, including severe hypoglycemia, when combined with insulin or an insulin secretagogue such as a sulfonylurea; a dose reduction of the secretagogue or insulin may be necessary.
• Acute gallbladder disease; if cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated.
• Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists; patients should tell their clinicians about any planned surgery or procedure.
• Most common reactions are nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation and asthenia. Pens must never be shared between patients, even with a new needle, because of bloodborne pathogen transmission risk. The currently marketed generic immediate-release label carries no boxed warning; the thyroid C-cell tumor boxed warning belonged to the discontinued extended-release product and does not apply here.

Sources

1. PubMed research on Exenatide · NIH · National Library of Medicine
2. DrugBank record for Exenatide · DrugBank
3. Active clinical trials for Exenatide · U.S. National Library of Medicine

Related compounds

Exenatide FAQ